Narrativa welcomes former CDISC CEO David Evans to Advisory Board

LOS ANGELES, JULY 9, 2024

Narrativa, the leading artificial intelligence (AI) automation company in the life sciences industry, is thrilled to announce the appointment of David “Dave” Evans, former CEO of CDISC, to its advisory board. With a distinguished career, Evans is recognized globally as a pioneer in developing and implementing sophisticated process and system solutions.

Evans has made significant contributions to the life sciences industry, notably as the architect of the first electronic drug submission to the Food and Drug Administration (FDA) in 1985. Coming full circle, Evans joins Narrativa at an inflection point for AI in the life sciences after Narrativa recently became the first company to have its AI-generated clinical trial regulatory documentation submitted to and accepted by the FDA.

Throughout his career, Evans has overseen countless electronic regulatory submissions and the development of complex clinical data warehouse systems. His expertise spans information standards, regulatory compliance, and quality governance. Evans joined CDISC after an eight-year tenure at Accenture, where he was the Principal Director, Global Head of Quality Governance and Regulatory Compliance for Accenture Life Sciences. Prior to that, he served as CIO of Octagon Research Solutions, which had been acquired by Accenture. He also previously served as Chair of the CDISC Advisory Council and as a member of the CDISC Board of Directors. Evans’s educational background includes an MS in Biomedical Engineering from Drexel University and a BS in Biology from Ursinus College.

“We are honored to welcome Dave Evans to our Advisory Board,” said Jennifer Bittinger, President of Narrativa. “Dave’s visionary leadership and deep expertise in regulatory compliance and information standards will be invaluable as we continue to innovate and enhance our AI-driven solutions. His experience aligns perfectly with our mission to revolutionize the clinical research process and bring life-saving treatments to market faster.”

“I am excited to join Narrativa’s Advisory Board and contribute to their groundbreaking work in AI and clinical research,” said Evans. “Narrativa is at the forefront of transforming the way we approach regulatory documentation and clinical trial processes with its AI platform and I look forward to helping guide their continued success and innovation in this vital field.”

Based in Los Angeles, Narrativa collaborates with an array of organizations within the life sciences industry, including pharma sponsors, contract research organizations (CROs), biotech companies, and regulatory bodies. Narrativa’s AI-powered platform employs advanced AI, namely natural language generation (NLG) and natural language processing (NLP), to process immense volumes of data. This produces clear and comprehensive smart regulatory reports with enhanced accuracy and efficiency.

About Narrativa

Narrativa® is the leading generative AI automation company focused on revolutionizing the Life Sciences field. Its proprietary and secure medical writing automation platform, equipped with built-in AI agents, quickly and accurately creates smart documentation such as CSRs (clinical study reports), patient narratives, TLFs (tables, listings, and figures), and redacted/anonymized files that empower pharmaceutical sponsors, biotechnology companies, and CROs (clinical research organizations). From database to delivery, Narrativa not only speeds up the clinical trial process and reduces errors, but authors complete documentation for medical writer review and submission to regulatory bodies—all without the need for teams to piece together parts of documents themselves. Accelerate the potential with Narrativa®.

For additional information, visit www.narrativa.com and follow on LinkedIn, Facebook, Instagram, and X.